Forty-six pairs of MM patients before and after treatment provided evidence for better consistency between abnormal metabolites and M protein, which enabled identification of new biomarkers to monitor disease activity or early recurrence, and evaluate treatment response and prognosis of MM. The gene discussed is MYOM2; the disease is Miyoshi myopathy.